Arilvax (PowderJect).
Celltech (formerly Medeva) had developed Arilvax, a single-dose, live, attenuated vaccine for the prevention of yellow fever, which the company launched in Europe. However, in October 2000, PowderJect acquired the vaccine as part of its acquisition of Celltech's vaccine business [381557], [384374]. In July 2001, PowderJect expected to re-launch Arilvax in the UK and, in the near future, Europe, following a manufacturing upgrade [414453], [443490]. By May 2000, Acambis (formerly Peptide Therapeutics), was developing the vaccine in the US under an exclusive license and phase III trials were underway [341301], [366663]. By September 2000, preparation for a BLA in the US had begun [382969]. By September 2001, the BLA submission was expected by mid-2002 [422760], [443490]. In September 1999, Peptide Therapeutics was predicting a US launch in the first half of 2001 with expected sales of around US $25 million per annum [340078], [341301].
Department of Pathology & Sealy Center for Vaccine Development University of Texas Medical Branch, Galveston 77555-0609, USA. abarrett@utmb.edu
Alan D T
AD
Barrett
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004345:Drug Industry / Q000331:legislation & jurisprudence* / Q000379:methods; D006801:Humans; D014765:Viral Vaccines / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D015004:Yellow Fever / Q000188:drug therapy / Q000276:immunology
D014765:Viral Vaccines